학술논문
Impact of oral, selective, allosteric tyrosine kinase 2 inhibitor, deucravacitinib, on psoriasis in patients with active psoriatic arthritis: results from a phase 2 trial
Document Type
Note
Author
Source
In: SKIN: Journal of Cutaneous Medicine . (SKIN: Journal of Cutaneous Medicine, 18 March 2024, 8(2):S383)
Subject
Language
English
ISSN
25741624